NIH Conference on the Future of Telehealth: Essential tools and technologies for clinical research and care . Telemed J E Health 2010 ; 16 :89–92Doarn CR, Portilla LM, Sayre MH. NIH conference on the future of telehealth: essential tools and technologies for clinical research and care: a...
We also chat with health tech reporter Brittany Trang about the claims that two drug developers, Absci and Generate:Biomedicines, have made about the capabilities of their artificial intelligence technologies, and why some experts are skeptical. For an explainer on the NIH funding c...
在这项纳入了 597 名猴痘入院患者的初步临床试验中,特考韦瑞并未缩短患者病程,但不论是用药组还是安慰剂组,患者死亡率均低于该国通常报告的猴痘死亡率(1.7% vs 3.6%),研究者推测,这可能与患者入院期间接受的高质量医疗护理有关。然而...
This paper contains theoretical assumptions about new technologies adoption, with the focus on ICT and mobile telephony. After that, information about adoption of these channels is presented. Finally, an analysis of these results with the conclusions is given.Ivana Jošanov...
NIH conference on the future of telehealth: essential tools and technologies for clinical research and care--a summary. Telemed J E Health. 2010;16(1):89-92. doi:10.1089/tmj.2009.0151.Doarn CR, Portilla LM, Sayre MH. NIH conference on the future of telehealth: essential tools and ...
The intramural research program was formerly a part of the Office of Research Services. The division specializes in developing and applying new technologies from engineering, mathematics and the physical sciences to address problems in biology and medicine....
doi:10.1161/circ.144.suppl_1.11350Shannon HallowaySusan W BuchholzManju DanielSally LemkeMargaret Bavisjanice A odiagaPhyllis PeltLynne T BraunSusan TafiniMelissa KalenskyOvid Technologies (Wolters Kluwer Health)Circulation
To address scientific challenges, the exRNA Communication program developed novel tools and technologies to isolate exRNA carriers and analyze their cargo. Here, we discuss the outcomes of the NIH Common Fund exRNA Communication program, as well as the evolution of exRNA as a scientific field ...
Company-financingDrug-discovery-technologiesInfluenza-virus-infections, preventionInfluenza-virus-vaccine, immunogenicityNational-Institutes-of-Health-USAVaccines, immunogenicity
doi:10.1161/str.50.suppl_1.TP60Dawn O KleindorferCharles J MoomawMichael MlynashJoseph P BroderickPooja KhatriJeffrey L SaverKathleen AlwellStephanie KempScott JanisClaudia MoyOvid Technologies (Wolters Kluwer Health)Stroke